• 027028

    Endovascular Superselective Intra-arterial infusion of Mesenchymal Stem Cells loaded with Delta-24 in a Canine Model


    Visish Srinivasan, Peter Kan, Frederick Lang, Elizabeth Shpall


    Introduction: Delta-24-RGD, an oncolytic adenovirus showing promise in clinical trials against glioblastoma. In an effort to enhance delivery of this virus, we recently demonstrated that human Mesenchymal Stem Cells loaded with Delta-24-RGD (hMSC-D24) are capable of eradicating glioblastoms in mouse models. However, there are no studies examining the safety of modern endovascular super-selective intra-arterial (ESSIA) injections of MSC-D24 in animals large enough to simulate human situations.

    Objective: Therefore, we undertook preclinical studies in canines to test the feasibility of delivering increasing doses of MSCs-D24 via ESSIA injections.

    Methods: The cerebral circulation was accessed via a transfemoral approach, and ESSIA infusions of GMP-grade hMSC-D24 were performed in the target vessels (ICA or P1) using clinical-grade microcatheters. Increasing concentrations of hMSC-D24 or particles (as a positive control) were injected into one hemisphere, and saline (negative control) was injected into the opposite hemisphere. Toxicity (stroke) was assessed by post-infusion angiography, MRI, and necropsy.

    Results: ESSIA injections were performed in 10 canines (anterior circulation, N=7; posterior circulation, N=3). In two positive controls, strokes were detected by all assays. Of 8 canines injected with hMSC-D24, escalating from 2x10^6 cells/20mL to 1x10^8 cells/10mL resulted in no strokes. In comparison, 1 (12%) of 8 hemispheres infused with saline had stroke. Two subjects were recovered and survived without morbidity for 24-hrs before being euthanized.

    Conclusions: This first-of-its-kind study simulating ESSIA infusion of MSCs-D24 demonstrates that hMSC-D24 can be infused safely at least up to doses of 1x10^8 cells/10mL. These findings support a clinical trial of ESSIA infusion of Delta-24-MSCs.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy